20.00
price down icon4.31%   -0.90
after-market Handel nachbörslich: 20.00
loading
Schlusskurs vom Vortag:
$20.90
Offen:
$20.68
24-Stunden-Volumen:
403.62K
Relative Volume:
1.35
Marktkapitalisierung:
$811.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-136.98M
KGV:
-4.9751
EPS:
-4.02
Netto-Cashflow:
$-126.63M
1W Leistung:
+3.57%
1M Leistung:
+1.47%
6M Leistung:
+8.78%
1J Leistung:
-28.42%
1-Tages-Spanne:
Value
$19.46
$21.20
1-Wochen-Bereich:
Value
$19.30
$21.86
52-Wochen-Spanne:
Value
$15.47
$36.37

Arrivent Biopharma Inc Stock (AVBP) Company Profile

Name
Firmenname
Arrivent Biopharma Inc
Name
Telefon
240-780-6356
Name
Adresse
18 CAMPUS BLVD., NEWTOWN SQUARE
Name
Mitarbeiter
52
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
AVBP's Discussions on Twitter

Vergleichen Sie AVBP mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
AVBP
Arrivent Biopharma Inc
20.00 846.27M 0 -136.98M -126.63M -4.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
412.22 104.45B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
469.36 60.95B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.60 59.11B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
812.95 49.23B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
320.94 35.92B 4.56B -176.77M 225.30M -1.7177

Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-10 Fortgesetzt Goldman Buy
2025-03-20 Eingeleitet B. Riley Securities Buy
2025-03-10 Eingeleitet Guggenheim Buy
2024-07-22 Eingeleitet Oppenheimer Outperform
2024-04-30 Eingeleitet H.C. Wainwright Buy
2024-02-20 Eingeleitet Citigroup Buy
2024-02-20 Eingeleitet Goldman Buy
2024-02-20 Eingeleitet Jefferies Buy
Alle ansehen

Arrivent Biopharma Inc Aktie (AVBP) Neueste Nachrichten

pulisher
05:48 AM

Analyzing ArriVent BioPharma Inc. with multi timeframe charts2025 Institutional Moves & Weekly Breakout Watchlists - newser.com

05:48 AM
pulisher
03:49 AM

Is ArriVent BioPharma The Next Big Player In Targeted Cancer Therapies? - RTTNews

03:49 AM
pulisher
12:42 PM

How ArriVent BioPharma Inc. stock reacts to Fed rate cutsJuly 2025 WrapUp & AI Forecast for Swing Trade Picks - newser.com

12:42 PM
pulisher
Oct 13, 2025

Why ArriVent BioPharma Inc. stock is favored by pension fundsMarket Risk Analysis & Weekly High Potential Alerts - newser.com

Oct 13, 2025
pulisher
Oct 10, 2025

What’s the recovery path for long term holders of ArriVent BioPharma Inc.July 2025 Institutional & Weekly Breakout Watchlists - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Is ArriVent BioPharma Inc. stock attractive after correctionWeekly Market Report & Low Volatility Stock Recommendations - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Should you hold or exit ArriVent BioPharma Inc. nowJuly 2025 Momentum & Accurate Trade Setup Notifications - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Can volume confirm reversal in ArriVent BioPharma Inc.July 2025 Intraday Action & AI Forecasted Entry/Exit Points - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

ArriVent BioPharma (NASDAQ:AVBP) Given Sell (D-) Rating at Weiss Ratings - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

Will ArriVent BioPharma Inc. stock see PE expansion2025 Stock Rankings & AI Forecasted Stock Moves - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

ArriVent BioPharma Secures Global Rights to MRG007 in Strategic Deal with Lepu Biopharma - MSN

Oct 08, 2025
pulisher
Oct 06, 2025

Is it too late to sell ArriVent BioPharma Inc.2025 Momentum Check & Fast Moving Stock Trade Plans - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Oct 06, 2025
pulisher
Oct 05, 2025

Analyzing drawdowns of ArriVent BioPharma Inc. with statistical toolsWeekly Trend Recap & Smart Money Movement Tracker - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

How moving averages guide ArriVent BioPharma Inc. tradingTrade Risk Assessment & Long-Term Safe Return Strategies - newser.com

Oct 03, 2025
pulisher
Sep 30, 2025

Certain Options of ArriVent BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 1-OCT-2025. - MarketScreener

Sep 30, 2025
pulisher
Sep 30, 2025

Certain Common Stock of ArriVent BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 1-OCT-2025. - MarketScreener

Sep 30, 2025
pulisher
Sep 29, 2025

ArriVent BioPharma Taps Brent S. Rice as Chief Commercial Officer - MyChesCo

Sep 29, 2025
pulisher
Sep 27, 2025

ArriVent BioPharma Reports Q1 2025 Financial Results and Highlights Key Achievements - MSN

Sep 27, 2025
pulisher
Sep 26, 2025

ArriVent Reports Promising Results for Firmonertinib in Lung Cancer Patients With Rare EGFR Mutations - MSN

Sep 26, 2025
pulisher
Sep 26, 2025

Can S.P.E.E.H. Hidroelectrica S.A. (E28) stock hold up in economic slowdownJuly 2025 Patterns & AI Powered Market Entry Strategies - newser.com

Sep 26, 2025
pulisher
Sep 25, 2025

Is it time to cut losses on ArriVent BioPharma Inc.2025 Institutional Moves & Fast Moving Market Watchlists - newser.com

Sep 25, 2025
pulisher
Sep 23, 2025

Custom watchlist performance reports with ArriVent BioPharma Inc. - newser.com

Sep 23, 2025
pulisher
Sep 23, 2025

Goldman Sachs Group Inc. Reduces Holdings in ArriVent BioPharma, Inc. $AVBP - MarketBeat

Sep 23, 2025
pulisher
Sep 22, 2025

ArriVent BioPharma appoints Brent Rice as chief commercial officer - Investing.com

Sep 22, 2025
pulisher
Sep 22, 2025

ArriVent BioPharma appoints Brent Rice as chief commercial officer By Investing.com - Investing.com Nigeria

Sep 22, 2025
pulisher
Sep 22, 2025

ArriVent Appoints Brent Rice as Chief Commercial Officer - citybiz

Sep 22, 2025
pulisher
Sep 22, 2025

ArriVent Biopharma appoints Brent Rice as chief commercial officer - TipRanks

Sep 22, 2025
pulisher
Sep 22, 2025

Arrivent appoints Brent S. Rice as Chief Commercial Officer - MarketScreener

Sep 22, 2025
pulisher
Sep 22, 2025

ArriVent BioPharma Names Brent S. Rice as CCO - MarketScreener

Sep 22, 2025
pulisher
Sep 22, 2025

ArriVent BioPharma Announces Appointment of Brent S. Rice as Chief Commercial Officer - Quiver Quantitative

Sep 22, 2025
pulisher
Sep 22, 2025

ArriVent Appoints Brent S. Rice as Chief Commercial Officer - The Manila Times

Sep 22, 2025
pulisher
Sep 22, 2025

Oncology Biotech ArriVent BioPharma Taps 25-Year Industry Veteran to Lead Lung Cancer Drug Launch - Stock Titan

Sep 22, 2025

Finanzdaten der Arrivent Biopharma Inc-Aktie (AVBP)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.75
price down icon 5.15%
$85.96
price up icon 1.45%
$32.75
price up icon 0.21%
$102.61
price up icon 0.30%
$161.38
price down icon 1.56%
biotechnology ONC
$320.94
price down icon 1.86%
Kapitalisierung:     |  Volumen (24h):